FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015143075> ?p ?o ?g. }

• W2015143075 endingPage "1461" @default.
• W2015143075 startingPage "1453" @default.
• W2015143075 abstract "Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients.BackgroundGlomerular filtration rate (GFR) is the best overall index of renal function in health and disease. Inulin and 51Cr-EDTA plasma clearances are considered the gold standard methods for estimating GFR. Unfortunately, these methods require specialized technical personnel over a period of several hours and high costs. In clinical practice, serum creatinine is the most widely used index for the noninvasive assessment of GFR. Despite its specificity, serum creatinine demonstrates an inadequate sensitivity, particularly in the early stages of renal impairment. Recently, cystatin C, a low molecular mass plasma protein freely filtered through the glomerulus and almost completely reabsorbed and catabolized by tubular cells, has been proposed as a new and very sensitive serum marker of changes in GFR. This study was designed to test whether serum cystatin C can replace serum creatinine for the early assessment of nephropathy in patients with type 2 diabetes.MethodsThe study was performed on 52 Caucasian type 2 diabetic patients. Patients with an abnormal albumin excretion rate (AER) were carefully examined to rule out non-diabetic renal diseases by ultrasonography, urine bacteriology, microscopic urine analysis, and kidney biopsy. Serum creatinine, serum cystatin C, AER, serum lipids, and glycosylated hemoglobin (HbA1c) were measured. GFR was estimated by the plasma clearance of 51Cr-EDTA. In addition the Cockcroft and Gault formula (Cockcroft and Gault estimated GFR) was calculated.ResultsCystatin C serum concentration progressively increased as GFR decreased. The overall relationship between the reciprocal cystatin C and GFR was significantly stronger (r = 0.84) than those between serum creatinine and GFR (r = 0.65) and between Cockcroft and Gault estimated GFR and GFR (r = 0.70). As GFR decreased from 120 to 20 mL/min/1.73 m2, cystatin C increased more significantly that serum creatinine, giving a stronger signal in comparison to that of creatinine over the range of the measured GFR. The maximum diagnostic accuracy of serum cystatin C (90%) was significantly better than those of serum creatinine (77%) and Cockcroft and Gault estimated GFR (85%) in discriminating between type 2 diabetic patients with normal GFR (!80 mL/min per 1.73 m2) and those with reduced GFR (!80 mL/min/1.73 m2). In particular, the cystatin C cut-off limit of 0.93 mg/L corresponded to a false-positive rate of 7.7% and to a false-negative rate of 1.9%; the serum creatinine cut-off limit of 87.5 μmol/L corresponded to a false-positive rate of 5.8% and to a false-negative rate of 17.0%.ConclusionsCystatin C may be considered as an alternative and more accurate serum marker than serum creatinine or the Cockcroft and Gault estimated GFR in discriminating type 2 diabetic patients with reduced GFR from those with normal GFR. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Glomerular filtration rate (GFR) is the best overall index of renal function in health and disease. Inulin and 51Cr-EDTA plasma clearances are considered the gold standard methods for estimating GFR. Unfortunately, these methods require specialized technical personnel over a period of several hours and high costs. In clinical practice, serum creatinine is the most widely used index for the noninvasive assessment of GFR. Despite its specificity, serum creatinine demonstrates an inadequate sensitivity, particularly in the early stages of renal impairment. Recently, cystatin C, a low molecular mass plasma protein freely filtered through the glomerulus and almost completely reabsorbed and catabolized by tubular cells, has been proposed as a new and very sensitive serum marker of changes in GFR. This study was designed to test whether serum cystatin C can replace serum creatinine for the early assessment of nephropathy in patients with type 2 diabetes. The study was performed on 52 Caucasian type 2 diabetic patients. Patients with an abnormal albumin excretion rate (AER) were carefully examined to rule out non-diabetic renal diseases by ultrasonography, urine bacteriology, microscopic urine analysis, and kidney biopsy. Serum creatinine, serum cystatin C, AER, serum lipids, and glycosylated hemoglobin (HbA1c) were measured. GFR was estimated by the plasma clearance of 51Cr-EDTA. In addition the Cockcroft and Gault formula (Cockcroft and Gault estimated GFR) was calculated. Cystatin C serum concentration progressively increased as GFR decreased. The overall relationship between the reciprocal cystatin C and GFR was significantly stronger (r = 0.84) than those between serum creatinine and GFR (r = 0.65) and between Cockcroft and Gault estimated GFR and GFR (r = 0.70). As GFR decreased from 120 to 20 mL/min/1.73 m2, cystatin C increased more significantly that serum creatinine, giving a stronger signal in comparison to that of creatinine over the range of the measured GFR. The maximum diagnostic accuracy of serum cystatin C (90%) was significantly better than those of serum creatinine (77%) and Cockcroft and Gault estimated GFR (85%) in discriminating between type 2 diabetic patients with normal GFR (!80 mL/min per 1.73 m2) and those with reduced GFR (!80 mL/min/1.73 m2). In particular, the cystatin C cut-off limit of 0.93 mg/L corresponded to a false-positive rate of 7.7% and to a false-negative rate of 1.9%; the serum creatinine cut-off limit of 87.5 μmol/L corresponded to a false-positive rate of 5.8% and to a false-negative rate of 17.0%. Cystatin C may be considered as an alternative and more accurate serum marker than serum creatinine or the Cockcroft and Gault estimated GFR in discriminating type 2 diabetic patients with reduced GFR from those with normal GFR." @default.
• W2015143075 created "2016-06-24" @default.
• W2015143075 creator A5015319367 @default.
• W2015143075 creator A5018051294 @default.
• W2015143075 creator A5018059398 @default.
• W2015143075 creator A5022457963 @default.
• W2015143075 creator A5026178919 @default.
• W2015143075 creator A5066210400 @default.
• W2015143075 creator A5082515576 @default.
• W2015143075 date "2002-04-01" @default.
• W2015143075 modified "2023-10-09" @default.
• W2015143075 title "Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients" @default.
• W2015143075 cites W1550111394 @default.
• W2015143075 cites W1966266726 @default.
• W2015143075 cites W1985572290 @default.
• W2015143075 cites W1990771236 @default.
• W2015143075 cites W1992816830 @default.
• W2015143075 cites W1999917583 @default.
• W2015143075 cites W2009278968 @default.
• W2015143075 cites W2012638831 @default.
• W2015143075 cites W2018956954 @default.
• W2015143075 cites W2022230104 @default.
• W2015143075 cites W2042272211 @default.
• W2015143075 cites W2044850321 @default.
• W2015143075 cites W2047970676 @default.
• W2015143075 cites W2051873425 @default.
• W2015143075 cites W2052502043 @default.
• W2015143075 cites W2053330911 @default.
• W2015143075 cites W2071643528 @default.
• W2015143075 cites W2075271694 @default.
• W2015143075 cites W2076365332 @default.
• W2015143075 cites W2077641457 @default.
• W2015143075 cites W2080199877 @default.
• W2015143075 cites W2088310780 @default.
• W2015143075 cites W2092665222 @default.
• W2015143075 cites W2102150307 @default.
• W2015143075 cites W2111982738 @default.
• W2015143075 cites W2113184926 @default.
• W2015143075 cites W2126359889 @default.
• W2015143075 cites W2141348928 @default.
• W2015143075 cites W2157825442 @default.
• W2015143075 cites W2158783623 @default.
• W2015143075 cites W2163784004 @default.
• W2015143075 cites W2317521667 @default.
• W2015143075 cites W2324579467 @default.
• W2015143075 cites W4237993189 @default.
• W2015143075 cites W4302070358 @default.
• W2015143075 doi "https://doi.org/10.1046/j.1523-1755.2002.00253.x" @default.
• W2015143075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11918752" @default.
• W2015143075 hasPublicationYear "2002" @default.
• W2015143075 type Work @default.
• W2015143075 sameAs 2015143075 @default.
• W2015143075 citedByCount "245" @default.
• W2015143075 countsByYear W20151430752012 @default.
• W2015143075 countsByYear W20151430752013 @default.
• W2015143075 countsByYear W20151430752014 @default.
• W2015143075 countsByYear W20151430752015 @default.
• W2015143075 countsByYear W20151430752016 @default.
• W2015143075 countsByYear W20151430752017 @default.
• W2015143075 countsByYear W20151430752018 @default.
• W2015143075 countsByYear W20151430752019 @default.
• W2015143075 countsByYear W20151430752020 @default.
• W2015143075 countsByYear W20151430752021 @default.
• W2015143075 countsByYear W20151430752022 @default.
• W2015143075 countsByYear W20151430752023 @default.
• W2015143075 crossrefType "journal-article" @default.
• W2015143075 hasAuthorship W2015143075A5015319367 @default.
• W2015143075 hasAuthorship W2015143075A5018051294 @default.
• W2015143075 hasAuthorship W2015143075A5018059398 @default.
• W2015143075 hasAuthorship W2015143075A5022457963 @default.
• W2015143075 hasAuthorship W2015143075A5026178919 @default.
• W2015143075 hasAuthorship W2015143075A5066210400 @default.
• W2015143075 hasAuthorship W2015143075A5082515576 @default.
• W2015143075 hasBestOaLocation W20151430751 @default.
• W2015143075 hasConcept C126322002 @default.
• W2015143075 hasConcept C126894567 @default.
• W2015143075 hasConcept C134018914 @default.
• W2015143075 hasConcept C159641895 @default.
• W2015143075 hasConcept C2777180221 @default.
• W2015143075 hasConcept C2779548226 @default.
• W2015143075 hasConcept C2779922275 @default.
• W2015143075 hasConcept C2780026642 @default.
• W2015143075 hasConcept C2780306776 @default.
• W2015143075 hasConcept C555293320 @default.
• W2015143075 hasConcept C71924100 @default.
• W2015143075 hasConceptScore W2015143075C126322002 @default.
• W2015143075 hasConceptScore W2015143075C126894567 @default.
• W2015143075 hasConceptScore W2015143075C134018914 @default.
• W2015143075 hasConceptScore W2015143075C159641895 @default.
• W2015143075 hasConceptScore W2015143075C2777180221 @default.
• W2015143075 hasConceptScore W2015143075C2779548226 @default.
• W2015143075 hasConceptScore W2015143075C2779922275 @default.
• W2015143075 hasConceptScore W2015143075C2780026642 @default.
• W2015143075 hasConceptScore W2015143075C2780306776 @default.
• W2015143075 hasConceptScore W2015143075C555293320 @default.
• W2015143075 hasConceptScore W2015143075C71924100 @default.
• W2015143075 hasIssue "4" @default.
• W2015143075 hasLocation W20151430751 @default.

• next